Editas Medicine (EDIT) Efficacy Raises The Bigger Question - Stifel

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/3/2026

1. AAPL
2. PLTR
3. DOX
4. VRTX
5. CRWD
6. CHKP
7. ON
8. HNGE
9. INSP
10. AMD

Go back to Editas Medicine (EDIT) Efficacy Raises The Bigger Question - Stifel

Editas Medicine Announces Positive Initial Clinical Data from Ongoing Phase 1/2 BRILLIANCE Clinical Trial of EDIT-101 for LCA10

September 29, 2021 9:00 AM EDT

No serious adverse events or dose-limiting toxicities observed to date

Efficacy signals in the mid-dose cohort provide initial support for clinical benefits

Treatment in the adult high-dose cohort continues and pediatric mid-dose cohort commencing

Data presented in an oral presentation at the International Symposium on Retinal Degeneration

Company to host a webcast today at 11:00 a.m. ET

CAMBRIDGE, Mass., Sept. 29, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing... More